Journal Article DZNE-2026-00595

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Quality of Life in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.

 ;  ;  ;  ;  ;  ;  ;

2026
Wiley New York, NY [u.a.]

Muscle & nerve 74(1), 59 - 67 () [10.1002/mus.70232]

This record in other databases:    

Please use a persistent id in citations: doi:

Abstract: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disorder of the nervous system that detrimentally influences health-related quality of life (HRQoL). Evidence regarding factors influencing HRQoL in CIDP is scarce. The present study aimed to evaluate the health status of CIDP patients using instruments that assess multiple domains of HRQoL and to identify predictors of HRQoL in a large sample of German patients.102 patients with CIDP - according to the criteria of the European Academy of Neurology/Peripheral Nerve Society - were recruited between January 2013 and June 2014 from specialized neuroimmunology clinics. Response variables were the global and domain scores of the European Quality of Life-5 Dimensions 3 Level Version (EQ-5D) instrument and the World Health Organization quality of life instrument (WHOQOL). Regressor variables included the use of intravenous immunoglobulin, the use of systemic corticosteroids, sex, age, disease duration, depression, comorbidities, cognition, and sensory deficits. A control group was not assessed; unmatched normative data derived from published sources served as comparison data.Compared to healthy population norms, HRQoL was lower among CIDP patients, with a mean EQ-5D index score of 0.68 (SD: 0.43) and mean visual analogue scale score of 53.8 (SD: 21.4). The lowest WHOQOL scores were found in the physical (M: 55.6, SD: 17.9) and global (M: 47.6, SD: 17.5) domains. Depression was identified as the most consistent correlate of HRQoL, with p < 0.01 across all dimensions.HRQoL is reduced in CIDP patients. Adjunct treatment of depression shows encouraging potential as a therapeutic approach to enhance HRQoL.

Keyword(s): Humans (MeSH) ; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: psychology (MeSH) ; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: drug therapy (MeSH) ; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: epidemiology (MeSH) ; Quality of Life: psychology (MeSH) ; Female (MeSH) ; Male (MeSH) ; Middle Aged (MeSH) ; Aged (MeSH) ; Adult (MeSH) ; Health Status (MeSH) ; Surveys and Questionnaires (MeSH) ; Depression: psychology (MeSH) ; CIDP ; HRQoL ; chronic inflammatory demyelinating polyneuropathy ; depression ; health‐related quality of life ; regression

Classification:

Contributing Institute(s):
  1. Parkinson Genetics (AG Gasser)
Research Program(s):
  1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2026
Database coverage:
Medline ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DEAL Wiley ; Ebsco Academic Search ; Essential Science Indicators ; IF < 5 ; JCR ; NationallizenzNationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Institute Collections > TÜ DZNE > TÜ DZNE-AG Gasser
Documents in Process
Public records
In process

 Record created 2026-06-08, last modified 2026-06-08


Restricted:
Download fulltext PDF Download fulltext PDF (PDFA)
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)